More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$321151486
EPS
-0.72
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
0.616538
Previous close
$3.61
Today's open
$3.55
Day's range
$2.98 - $3.60
52 week range
$2.98 - $8
show more
CEO
Sergio Traversa
Employees
17
Headquarters
Coral Gables, FL
Exchange
NASDAQ Capital Market
Shares outstanding
106694846
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
Former ADSTILADRIN® global clinical development leader brings extensive uro-oncology expertise as Relmada prepares to initiate the Phase 3 SPECTRUM program for NDV-01 Former ADSTILADRIN® global clinical development leader brings extensive uro-oncology expertise as Relmada prepares to initiate the Phase 3 SPECTRUM program for NDV-01
GlobeNewsWire • Nov 16, 2026

What Relmada Therapeutics (RLMD) Said on Its Q3 Earnings Call
Relmada Therapeutics NASDAQ: RLMD expects to submit applications for its bladder cancer treatment candidate NDV-01 and Prader-Willi syndrome program sepranolone by the end of 2026, executives said on the company's third-quarter earnings call.
MarketBeat • Nov 13, 2026

Relmada Therapeutics, Inc. (RLMD) Q3 2026 Earnings Call Transcript
Relmada Therapeutics, Inc. (RLMD) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 13, 2026

Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
NDV-01 CMC program on track to submit the IND by year-end 2026, with initiation of the registrational Phase 3 SPECTRUM program upon IND clearance Long-term extension NDV-01 Phase 2 data demonstrate continued durability of response: 86% of 12-month complete responders remained in complete response at 18 months, with no Grade ≥3 treatment-related adverse events or discontinuations Registrational Phase 3 program renamed SPECTRUM; two independent registrational pathways in NMIBC remain unchanged Cash, cash equivalents and short-term investments of approximately $202.1 million as of September 30, 2026, expected to fund operations through 2029 CORAL GABLES, Fla., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a business update, including 18-month results from the NDV-01 Phase 2 study, the registrational Phase 3 SPECTRUM program, and continued progress toward the planned year-end 2026 Investigational New Drug (IND) submission for NDV-01 and sepranolone.
GlobeNewsWire • Nov 12, 2026

Relmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in London
CORAL GABLES, Fla., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in London, UK, from November 16 - 19, 2026.
GlobeNewsWire • Nov 4, 2026

Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026
CORAL GABLES, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, November 12, 2026 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2026, and recent business progress.
GlobeNewsWire • Nov 3, 2026

5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
Zacks Investment Research • Sep 14, 2026

Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference being held in Boston, MA, from September 8 - 10, 2026.
GlobeNewsWire • Sep 1, 2026

After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)
Relmada Therapeutics (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks Investment Research • Aug 31, 2026

Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now
Relmada Therapeutics (RLMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Zacks Investment Research • Aug 25, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Relmada Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.